Indian Biosimilars: Going Global
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Address: No. 28, Mehta Vora Chamber, Mahendra Mansion, Babu Genu RoadMumbai – 400 002, Maharashtra, India
Tel: 91 22 26101320
Web: http://www.apexdrugs.com/
Started in 1979 as an Importer for Bulk Drug and API’s, Today Apex Drug House has diversified into manufacturing of pharmaceutical formulations and is at the forefront in developing and marketing for International markets. Our products are manufactured in WHO GMP, NAFDAC, NDA and FDB certified facilities where various forms of pharmaceuticals like Tablets, Capsules, Syrups, Ointments, Lozenges, Dry Powder Injections, Liquid Injections, Ophthalmic solutions and Aerosols are manufactured. Additionally Apex also manufactures Herbals, Soft Gelatin Capsules, Lozenges and specialty products like Mosquito Repellents and Condoms. We focus on providing quality products and continually invest our time and resources in the quest to achieve higher levels of quality products and earned reputation from our clients.
Apex Drug House has a strong presence in regions like Latin America, South East Asia, CIS and African regions. With the know-how and the capacity of our plants we are close to our customers in important markets. We provide a worldwide supply chain, making sure that products will be available when and where they are needed. Our strong portfolio of products gives us an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world, regardless of geographic and socio-economic barriers.
Apex Drug House is a fully integrated pharmaceutical formulation company at the forefront in developing, manufacturing and marketing of formulations for International markets. Additionally Apex also manufactures Herbals, and specialty products like Mosquito Repellents and Condoms. Our strong portfolio of products gives us an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world.
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Alexandre Williams, founder and managing director of Athena, an international company with an Indian manufacturing basis specialized in life cycle products, provides insights into some key trends shaping India’s pharmaceutical…
As the founder and chairman of Alves Group, a key Indian player in medical devices with an extensive portfolio, Randolph Alves shares the challenges India needs to overcome to remain…
Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive care, and other therapeutic areas, provides us with an insightful overview of the main…
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’…
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
R.S. Subramanian, country manager and Sandeep Juneja, vice president – Sales and Marketing, DHL Express India, explain why the world’s leading express logistics company is a trusted and accountable service…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty…
Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized…
See our Cookie Privacy Policy Here
